EUVIMEDAtrasti EUVIMED
Crossref

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy

Birgit S Geurts iD, Laurien J Zeverijn iD, Jade M van Berge Henegouwen iD, Hanneke van der Wijngaart iD, Louisa R Hoes iD, Gijs F de Wit, Ilse Ac Spiekman iD, Thomas W Battaglia iD, Daphne M van Beek iD, Paul Roepman iD, Anne Ml Jansen iD, Wendy Wj de Leng iD and 7 more

The Journal of Pathology · 2024-07 · 263 (3) · 288-299

DOI: 10.1002/path.6279 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2024-05-15. Written by Birgit S Geurts and 18 co-authors. Institution: Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Major MEDLINE topics: Microsatellite Instability, DNA Mismatch Repair, Immune Checkpoint Inhibitors. Cited 12 times so far (Crossref); 45 references. Funded by: Stelvio for Life Foundation, Dutch Cancer Society, Amgen.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile with approved targeted and immunotherapies outside the labeled indication. Importantly, patients undergo a tumor biopsy for whole‐genome sequencing (WGS) which allows for a WGS‐based evaluation of routine diagnostics. Notably, we observed that not all biopsies of patients with dMMR/MSI‐positive tumors as determined by routine diagnostics were classified as microsatellite‐unstable by subsequent WGS. Therefore, we aimed to evaluate the discordance rate between routine dMMR/MSI diagnostics and WGS and to further characterize discordant cases. We assessed patients enrolled in DRUP with dMMR/MSI‐positive tumors identified by routine diagnostics, who were treated with immune checkpoint blockade (ICB) and for whom WGS data were available. Patient and tumor characteristics, study treatment outcomes, and material from routine care were retrieved from the patient medical records and via Palga (the Dutch Pathology Registry), and were compared with WGS results. Initially, discordance between routine dMMR/MSI diagnostics and WGS was observed in 13 patients (13/121; 11%). The majority of these patients did not benefit from ICB (11/13; 85%). After further characterization, we found that in six patients (5%) discordance was caused by dMMR tumors that did not harbor an MSI molecular phenotype by WGS. In six patients (5%), discordance was false due to the presence of multiple primary tumors ( n = 3, 2%) and misdiagnosis of dMMR status by immunohistochemistry ( n = 3, 2%). In one patient (1%), the exact underlying cause of discordance could not be identified. Thus, in this group of patients limited to those initially diagnosed with dMMR/MSI tumors by current routine diagnostics, the true assay‐based discordance rate between routine dMMR/MSI‐positive diagnostics and WGS was 5%. To prevent inappropriate ICB treatment, clinicians and pathologists should be aware of the risk of multiple primary tumors and the limitations of different tests. © 2024 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Microsatellite InstabilityDNA Mismatch RepairImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedImmunotherapyWhole Genome SequencingAdultBiomarkers, TumorNeoplasmsAged, 80 and overColorectal Neoplasms

Author keywords

immune checkpoint blockadeimmunohistochemistrymicrosatellite instabilitymismatch repair deficiencypolymerase chain reactionwhole‐genome sequencing

Substances

Immune Checkpoint InhibitorsBiomarkers, Tumor

Authors and institutions

  • Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Oncode Institute, Utrecht, The Netherlands.
  • Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands.
  • Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Hartwig Medical Foundation, Amsterdam, The Netherlands.

ORCID profiles: Birgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, Louisa R Hoes, Ilse Ac Spiekman, Thomas W Battaglia, Daphne M van Beek, Paul Roepman, Anne Ml Jansen, Wendy Wj de Leng, Annegien Broeks, Mariette Labots, Carla Ml van Herpen, Hans Gelderblom, Henk Mw Verheul, Petur Snaebjornsson, Emile E Voest

Funding

  • Stelvio for Life Foundation
  • Dutch Cancer Society
  • Amgen
  • AstraZeneca
  • Bristol Myers Squibb
  • Eisai
  • GlaxoSmithKline
  • Janssen

Cite

APA

Geurts, B. S., Zeverijn, L. J., van Berge Henegouwen, J. M., van der Wijngaart, H., Hoes, L. R., de Wit, G. F., Spiekman, I. A., Battaglia, T. W., van Beek, D. M., Roepman, P., Jansen, A. M., de Leng, W. W., Broeks, A., Labots, M., van Herpen, C. M., Gelderblom, H., Verheul, H. M., Snaebjornsson, P., & Voest, E. E. (2024). Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy. The Journal of Pathology, 263(3), 288-299. https://doi.org/10.1002/path.6279

Vancouver

Geurts BS, Zeverijn LJ, van Berge Henegouwen JM, van der Wijngaart H, Hoes LR, de Wit GF, et al. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy. The Journal of Pathology. 2024;263(3):288-299. doi:10.1002/path.6279

BibTeX
@article{Geurts2024,
  author = {Geurts, Birgit S and Zeverijn, Laurien J and van Berge Henegouwen, Jade M and van der Wijngaart, Hanneke and Hoes, Louisa R and de Wit, Gijs F and Spiekman, Ilse Ac and Battaglia, Thomas W and van Beek, Daphne M and Roepman, Paul and Jansen, Anne Ml and de Leng, Wendy Wj and Broeks, Annegien and Labots, Mariette and van Herpen, Carla Ml and Gelderblom, Hans and Verheul, Henk Mw and Snaebjornsson, Petur and Voest, Emile E},
  title = {Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {263},
  number = {3},
  pages = {288--299},
  doi = {10.1002/path.6279}
}
Start for free →